Operationalization of Bispecific Antibodies in Non-Hodgkin Lymphoma (NHL)

Panelists discuss how bispecific antibodies are transforming the treatment landscape for non-Hodgkin lymphoma by enhancing T cell engagement and targeting malignant B cells effectively.

Panelists discuss how to operationalize bispecific antibody (BsAb) therapy in community practices, summarizing the toxicities associated with CD3×CD20 BsAbs and presenting consensus recommendations for their management.

Dr Graff discusses how to operationalize bispecific antibody (BsAb) therapy in community practices by summarizing the toxicities associated with CD3×CD20 BsAbs and presenting consensus recommendations for their management.

Panelists discuss how they developed their protocols for administering bispecific antibodies and monitoring and managing associated adverse events.

Dr Graff discusses how they developed protocols for administering bispecific antibodies and monitoring and managing associated adverse events.

Panelists discuss how they manage cytokine release syndrome and the necessary pretreatment testing to ensure patient safety and effective therapy.

Panelists discuss the recommendations for evaluating, identifying, and managing cytokine release syndrome (CRS), covering the pretreatment phase, patient education, treatment location, premedications, CRS management, dose modifications, and the community oncology perspective.

Dr Graff discusses the recommendations for evaluating, identifying, and managing cytokine release syndrome (CRS), covering the pretreatment phase, patient education, treatment location, premedications, CRS management, dose modifications, and the community oncology perspective.

Panelists discuss the recommendations for identifying, evaluating, and managing neurological toxicities, including workup and evaluation, grading of toxicity, and overall management. They also address other important toxicities.

Dr Graff discusses the recommendations for identifying, evaluating, and managing neurological toxicities, including workup and evaluation, grading of toxicity, and overall management, also addressing other important toxicities.

Dr Graff discusses the differences and similarities in managing adverse events associated with bispecific antibodies in non-Hodgkin lymphoma compared to other therapeutic indications, such as multiple myeloma and non–small cell lung cancer.

Dr Graff discusses her standard approach when initiating bispecific antibody treatment for patients, including whether to refer to an academic center or provide treatment in the community setting and how to manage hospitalization if required.

Panelists discuss how they collaborate with community oncology centers when receiving patient referrals for initial or step-up dosing, returning patients to community practices for maintenance dosing, and managing grade 3/4 adverse events related to cytokine release syndrome or neurotoxicity.

Panelists discuss their perceptions of the future for patients treated with bispecific antibodies for non-Hodgkin lymphoma, highlighting key unmet needs and sharing clinical pearls for community oncologists.

Dr Graff discusses perceptions of the future for patients treated with bispecific antibodies for non-Hodgkin lymphoma, highlighting key unmet needs and sharing clinical pearls for community oncologists.